|1.||Hande, M Prakash: 2 articles (01/2014 - 01/2014)|
|2.||Gurung, Resham Lal: 2 articles (01/2014 - 01/2014)|
|3.||Tsuruo, Takashi: 2 articles (01/2007 - 07/2002)|
|4.||Seimiya, Hiroyuki: 2 articles (01/2007 - 07/2002)|
|5.||Kazemi, Ahmad: 1 article (11/2015)|
|6.||Safa, Majid: 1 article (11/2015)|
|7.||Fatemi, Ahmad: 1 article (11/2015)|
|8.||Haberichter, Jarod: 1 article (10/2015)|
|9.||Nguyen, Marie L: 1 article (10/2015)|
|10.||Abbasi, Imran: 1 article (10/2015)|
|1.||Lung Neoplasms (Lung Cancer)
|2.||Acute Promyelocytic Leukemia
|3.||Hepatocellular Carcinoma (Hepatoma)
02/15/2015 - "The purpose of the present study was to investigate the radiosensitizing effect of telomerase inhibitor MST-312 and the corresponding mechanism in the human hepatoma cell line HepG2. "
02/15/2015 - "Radiosensitization to X-ray radiation by telomerase inhibitor MST-312 in human hepatoma HepG2 cells."
01/01/2011 - "Interestingly, MST312 has a strong antiproliferative effect on lung CSCs and induces p21, p27 and apoptosis in the whole tumor population. "
01/01/2014 - "Our work demonstrates potential importance for the establishment of antitelomerase cancer therapy using MST-312 along with PARP-1 inhibition in breast cancer therapy."
01/01/2007 - "Thus, overexpression of tankyrase 1 in telomerase-positive cancer cells confers resistance to telomerase inhibitors, such as MST-312, whereas pharmacological inhibition of tankyrase 1 enhances telomere shortening by MST-312. "
07/01/2002 - "Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991."
|5.||Osteosarcoma (Osteogenic Sarcoma)
|1.||Telomerase (Telomerase Reverse Transcriptase)
|2.||epigallocatechin gallate (epigallocatechin-3-gallate)
|4.||Catechin (Z 7300)